@FiercePharma: More layoffs for $LLY: Eli Lilly to cut 100s of sales people in neuroscience, CV and men's health. Report | Follow @FiercePharma
@EricPFierce: C'est la vie. Sanofi finds the politics of downsizing in France a war of attrition. Report | Follow @EricPFierce
> Drugmakers have struck a deal with the Swiss government to accept lower payments in exchange for a promise of reducing drug approval times to as few as 60 days. Story
> ThromboGenics' partner Alcon has launched Jetrea (ocriplasmin), the first medicine for the treatment of vitreomacular traction (VMT) in the U.K. More
> Novartis ($NVS) is preparing for manufacturing of a new vaccine to fight the newest strain of bird flu through a faster process that has allowed government-backed researchers to begin testing a "seed" strain of the virus made from the genetic code posted on the Internet. Story
> Teva Pharmaceutical Industries ($TEVA) has started the process of cutting costs by improving procurement costs and reducing the footprint of its manufacturing network, CEO Jeremy Levin said. Story
> The FDA has approved Warner Chilcott's ($WCRX) 200 mg strength Doryx delayed-release antibiotic tablets, and the company intends to launch them in the U.S. in July. Release
> BTG's Varisolve treatment for varicose veins has been accepted for review by the FDA, putting it on track for potential approval and launch during the first half of 2014. Story
@FierceMedDev: Dx startup On-Q-ity shuts down. DxExtra story | Follow @FierceMedDev
@MarkHFierce: Altura Medical drew in $6M in new financing for AAA stent graft develpment, according to a regulatory filing. Story | Follow @MarkHFierce
@DamianFierce: Boston Scientific is launching a new, FDA-approved neuromodulation device for chronic back pain. Article | Follow @DamianFierce
> Medtronic launches FDA-targeted study for pain devices. News
> Life Tech snags Korean reagents outfit amid bidding war. News
> Med tech industry blasts Obama's proposed FY 14 budget. Item
Biotech News
@FierceBiotech: Firm ranks top 5 biotech deals in evolving pharma R&D landscape. Report | Follow @FierceBiotech
@JohnCFierce: Another thought on $GSK: If it gets over tox issue, drisapersen is probably headed for approval, barring a nasty efficacy surprise in Ph3. | Follow @JohnCFierce.
@RyanMFierce: Just heard from ex-FDA CIO Eric Perakslis. We'll have more on his next move soon, hopefully. News on his departure: Story | Follow @RyanMFierce
> Firm ranks top 5 biotech deals in evolving pharma R&D landscape. Report
> Boehringer Ingelheim fuels gene therapy startup focused on eye diseases. Article
> GlaxoSmithKline measures 38-meter leap over placebo in Duchenne walking test. News
And Finally... According to a new report from orphan drug specialist Shire ($SHPG), it can take more than 5 to 7 years for a patient with a rare disease to receive a proper diagnosis, averaging visits to 8 doctors on average and generally involving two or three 2-3 misdiagnoses before landing on the correct one. Report